Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MAX mutations status in Swedish patients with pheochromocytoma and paraganglioma tumours.

Familial cancer - 1 Mar 2014

Crona Joakim, Maharjan Rajani, Delgado Verdugo Alberto, Stålberg Peter, Granberg Dan, Hellman Per, Björklund Peyman

Abstract excerpt

Pheochromocytoma (PCC) and Paraganglioma are rare tumours originating from neuroendocrine cells. Up to 60% of cases have either germline or somatic mutation in one of eleven described susceptibility loci, SDHA, SDHB, SDHC, SDHD, SDHAF2, VHL, EPAS1, RET, NF1, TMEM127 and MYC associated factor-X (MAX). Recently, germline mutations in MAX were found to confer susceptibility to PCC and paraganglioma (PGL). A...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal Gland Neoplasms
Share to Basic Helix-Loop-Helix Leucine Zipper Transcription Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Frequency

Share to Genetic Predisposition to Disease

Share to Paraganglioma

Share to Pheochromocytoma

Share to Polymorphism, Single Nucleotide

Share to Sweden

Source

Identifiers

PMID: 23743562
DOI: 10.1007/s10689-013-9666-3

Genes

MAX
EPAS1
MYC
RET
SDHA
SDHAF2
SDHB
SDHC
SDHD
VHL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MAX mutations status in Swedish patients with pheochromocytoma and paraganglioma tumours.PMID 23743562Read ↗

Testing new susceptibility genes in the cohort of apparently sporadic phaeochromocytoma/paraganglioma patients with clinical characteristics of hereditary syndromes.Semantic proximity Read ↗

Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma.Semantic proximity Read ↗

Novel SDHB and TMEM127 Mutations in Patients with Pheochromocytoma/Paraganglioma Syndrome.Semantic proximity Read ↗

MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma.Semantic proximity Read ↗

Genotype and clinical phenotype characteristics of MAX germline mutation-associated pheochromocytoma/paraganglioma syndrome.Semantic proximity Read ↗

Integrative genetic characterization and phenotype correlations in pheochromocytoma and paraganglioma tumours.Semantic proximity Read ↗

Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma.Semantic proximity Read ↗

Next-generation sequencing in the clinical genetic screening of patients with pheochromocytoma and paragangliomaSemantic proximity Read ↗

[Genetics of paragangliomas and pheochromocytomas].Semantic proximity Read ↗

Clinical exome next‑generation sequencing panel for hereditary pheochromocytoma and paraganglioma diagnosisSemantic proximity Read ↗

Profiling of Somatic Mutations in Phaeochromocytoma and Paraganglioma by Targeted Next Generation Sequencing AnalysisSemantic proximity Read ↗

Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.